Adipotide Research Reference

Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.

Researched for: adipose vasculature and metabolic models

Metabolic Research peptide Lyophilized verified

Also known as: FTP peptide, Fat-targeted proapoptotic peptide

Quick Facts

Reference Sizes
2 mg, 5 mg, 10 mg
Calculator
Preset available
Storage
Lyophilized: store at -20 deg C. After reconstitution: refrigerate 2-8 deg C; verify beyond-use timing against source COA. Limited human safety data exists.
Solubility
Study formulation is peptide- and vehicle-specific; no validated human formulation exists

Catalog Description

Adipotide (FTPP, Fat-Targeted Proapoptotic Peptide) is a synthetic peptidomimetic studied for its ability to bind the prohibitin receptor on the vasculature supplying white adipose tissue, inducing localized apoptosis and disrupting blood supply to fat tissue - a fundamentally different mechanism from AOD-9604, which promotes lipolysis in existing fat cells rather than destroying their vascular supply. Development has been primarily preclinical/early-stage; independent, large-scale human efficacy and safety data remain limited.

Catalog descriptions reflect research context only. Not a medical claim or treatment recommendation.

Research Profile

Half-Life
Human pharmacokinetics have not been published. Preclinical (rhesus monkey) studies report a plasma half-life of roughly 30-60 minutes after subcutaneous injection; this is preclinical animal data only and no human trial or dosing figure exists.
Onset
Weight and adipose-tissue changes were observed over 4 weeks in obese nonhuman primates
Administration Routes (Research)
Subcutaneous (SC)

Reported Research Effects

Reported Research Side Effects

Data source: Primary mouse and nonhuman-primate adipose-vasculature studies

Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.

Route-Specific Research Protocols

Amounts and schedules are separated by administration route. Evidence badges distinguish labels, human studies, preclinical work, community reports, and evidence gaps.

Label / guideline Human study Community only Preclinical only Not established
Subcutaneous (SC) Preclinical only

0.43 mg/kg once daily

Frequency / timing
Daily
Duration / setting
4 weeks
Technique
SC
Evidence
Preclinical / laboratory study

Context: published obese-rhesus-monkey study; not a human protocol

Formulation: Route-specific sterile formulation and professional handling requirements apply; concentration cannot be inferred from an oral or topical product.

Route safety: Non-human or laboratory exposure. It cannot be converted into a human dose.

Do not convert an amount between routes. Bioavailability, formulation, sterility, monitoring, and clinical context differ by route. Research-use context only; independently verify every cited source.

Sources

Reversal of obesity by targeted ablation of adipose tissue — Nature Medicine
https://doi.org/10.1038/nm1048
A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys — PubMed (NIH)
https://pubmed.ncbi.nlm.nih.gov/22072637/

Suggest a community source

Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.

Related Research Tools

Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.

Scroll to Top